Proteomics International Laboratories Ltd. (AU:PIQ) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Proteomics International Laboratories unveils a breakthrough in esophageal cancer detection with its PromarkerEso blood test, demonstrating a remarkable 94% accuracy in identifying esophageal adenocarcinoma. This less invasive test could revolutionize the current screening process, offering a potential to significantly improve early diagnosis rates and outcomes for one of the deadliest cancers. With the current screening’s high costs and late diagnoses, the PromarkerEso test not only promises substantial healthcare savings but also a leap forward in patient survival prospects.
For further insights into AU:PIQ stock, check out TipRanks’ Stock Analysis page.